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Abstract Mitochondrial dysfunction is putatively central
to glioblastoma (GBM) pathophysiology but there has been
no systematic analysis in GBM of the proteins which are
integral to mitochondrial function. Alterations in proteins
in mitochondrial enriched fractions from patients with
GBM were defined with label-free liquid chromatography
mass spectrometry. 256 mitochondrially-associated pro-
teins were identified in mitochondrial enriched fractions
and 117 of these mitochondrial proteins were markedly
(fold-change C2) and significantly altered in GBM
(p B 0.05). Proteins associated with oxidative damage
(including catalase, superoxide dismutase 2, peroxiredoxin
1 and peroxiredoxin 4) were increased in GBM. Protein–
protein interaction analysis highlighted a reduction in
multiple proteins coupled to energy metabolism (in par-
ticular respiratory chain proteins, including 23 complex-I
proteins). Qualitative ultrastructural analysis in GBM with
electron microscopy showed a notably higher prevalence of
mitochondria with cristolysis in GBM. This study high-
lights the complex mitochondrial proteomic adjustments
which occur in GBM pathophysiology.
Keywords Glioblastoma  Mitochondria 
Clinical proteomics
Introduction
Survival times of patients with glioblastoma (GBM; WHO-
IV glioma), the most frequent and malignant type of adult
brain tumour, remain dismal [1]. Proteomic analyses of
glioma have identified numerous altered proteins but have
mostly concentrated on whole cell lysates and been dom-
inated by the high abundance proteins [2]. Prospective
proteomic studies need to analyse relevant subcellular
proteomes and assess protein–protein interactions between
altered proteins to gain further insight into glioma patho-
physiology and development of targeted therapies.
Mitochondrial dysfunction plays an important role in the
pathogenesis of GBM [3–5]. Mitochondria are essential
cellular organelles involved in numerous complex physio-
logical processes including energy generation, regulation
of cellular proliferation and apoptosis [5]. GBM, like many
malignant cancers, favour abnormal energy production via
aerobic glycolysis, and show an inherent resistance to
apoptosis [6–8]. To provide an insight into mitochondrial
dysfunction in GBM, we have quantified the proteomic
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alterations in mitochondrial fractions from GBM using a
label-free proteomics (LC–MS) approach. We highlight the
extensive interactions between the altered proteins in
relation to oxidative damage and energy metabolism, as
well as proteins that are associated with the nuclear tran-
scription factor hepatocyte nuclear factor 4alpha (HNF4A),
which plays a pivotal role in gut neoplasia and the targeting
of oxidoreductase-related genes [9].
Materials and methods
Brain samples were obtained from patients undergoing
resective brain tumour surgery after informed written
consent (ethical approval: LREC/2004/4/16). GBM and
control samples were resected from viable tumour tissue
and peritumoural brain respectively (patient C1 as excep-
tion; see supplementary S1 for details). Peritumoural-con-
trol brain was determined using a BrainLAB MRI guided
system (merged T1 contrast enhanced plus T2). For pro-
teomics, fresh samples were snap-frozen immediately fol-
lowing resection and stored at -70 C prior to
mitochondrial extraction. Irrespective of the pathology, the
global proteomic signature of individual peritumoural-
control samples could not be differentiated from the group
proteomic signature (supplementary S1). For electron
microscopy, samples were placed immediately after sur-
gical excision into fixative (4 %-paraformaldehyde, 5 %-
glutaraldehyde, 0.08 M sodium-cacodylate-buffer, pH 7.2).
Mitochondrial-enriched fractions were prepared from
GBM (n = 6) and peritumoural-control brain (n = 6)
using the Human Tissue Mitochondria-Isolation Kit (Mi-
tosciences). Immunoblotting with COXI, COXIV and
VDAC1 was performed on all samples prior to proteomic
analysis to check the integrity of the mitochondrial-enri-
ched fractions.
Mitochondrial Proteomics of GBM using LC–MS
Protein extracts (100 lg) from mitochondrial fractions
were digested and cleaned on SCX column [10]. Capillary–
HPLC–MSMS data were acquired using an on-line system
consisting of a micro-pump coupled to a hybrid LTQ-Or-
bitrap XL instrument (using Xcalibur 2.0.7). HPLC–MS
methods have been described previously [10–12].
LC–MS runs were analysed using the label-free inten-
sity analysis software Progenesis (NonlinearDynamics,
UK). MSMS data were searched using MASCOT Ver-
sion2.3 against a human plus-contaminant IPI database
with 55413 sequences downloaded from www.ebi.ac.uk
(v3.42). Variable methionine oxidation, STY phosphory-
lation, protein N-terminal acetylation and fixed cysteine
carbamidomethylation were used in searches.
Progenesis normalises sample intensities and calculates
protein intensities from MS peak data as the sum of MS-
peak intensities of identified peptides. Protein intensities
were used as a relative abundance measure between sam-
ples. Within group means were calculated to determine the
fold-change and this data was used to calculate the p-values
using one-way ANOVA. The data were converted using
Pride converter v2.5.4 [13] and are available on the public
data repository PRIDE (http://www.ebi.ac.uk/pride/;
accession numbers 20946-20957). All proteins identified
with C2 peptides are listed in supplementary S2. Differ-
entially expressed proteins were only considered significant
when detected by C2 peptides, C2-fold-change and
p B 0.05 for protein intensity change. Hierarchical clus-
tering on the normalized protein intensity was performed
using Rheatmap2.
Bioinformatic analysis of subcellular localisation
and protein–protein interactions
All quantified proteins were uploaded to the Database for
Annotation, Visualization and Integrated Discovery
(DAVID) (http://david.abcc.ncifcrf.gov [14, 15]) to deter-
mine subcellular localization based on gene-ontology
(GO). Cognizant of the fact that mitochondrial preparations
are enriched in, but are not exclusively mitochondrial
proteins, significantly altered proteins (p B 0.05, C2-fold-
change) included in the GO term mitochondrion
(GO:0005739) were identified from the master list, filtered
out, reported and used for network analysis.
Identifiers for altered proteins were uploaded to Inge-
nuity Pathway Analysis (IPA; http://www.ingenuity.com).
Interactomes were algorithmically generated based on
direct relationships (physical interactions and/or associa-
tions) between eligible proteins. Protein–protein interaction
scores are putatively a measure of probability for the in-
teractomes [16].
Mitochondrial morphology with electron microscopy
(EM)
Following a minimum of 20 h in aldehyde fixative, GBM
(n = 6) and peritumoural-control (n = 7) biopsies were
dissected into 1–2 mm3 pieces suitable for EM processing.
Processing, embedding and staining were performed, as
described [17]. Evaluation of tissue fixation was carried out
by an assessor, blinded to the status of the tissue. Only
samples judged to be well fixed under light microscopy
were submitted for further analysis.
EM sections were evaluated on a JEOL-CX-100-II
transmission electron microscope at 80009 magnification.
Images were captured within 3 grid squares selected in a
predetermined unbiased pattern.
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A multiple squares grid mask was superimposed on the
digitised electron micrographs. Mitochondria that lay
beneath an intersection were evaluated on the basis of
morphology, into one of three classes: normal (with cristae
clearly visible over [50 % of the matrix), abnormal
(swollen with most of the matrix lost), or uncertain (fewer
than normal cristae or condensed) (see supplementary S3).
The assessor was blinded to the nature of the tissue sam-
ples. A minimum of 119 mitochondria were assessed per
tissue sample.
Results
Overview of proteomic data from mitochondrial
fractions
A total of 902 proteins were identified. Hierarchical clus-
tering of the 902 normalized protein intensities revealed
two major clusters corresponding to GBM and peritumo-
ural-control cohorts (Fig. 1a). Western-blotting using
markers for outer (VDAC1) and inner (COX1, COXIV)
mitochondrial membranes indicated that all three proteins
were present in the mitochondrial-enriched fraction and
absent in the post-mitochondrial supernatant fraction from
GBM and peritumoural-control samples (supplementary
S4). These data indicate that there has been minimal
breakdown of mitochondrial membranes during the frac-
tionation procedure, and that mitochondrial fractionation or
integrity is not different in GBM compared to peritumo-
ural-control brain.
Alterations in the mitochondrial proteome of GBM
The 902 proteins identified by mass spectrometry were
categorised using DAVID and 256 proteins were classified
as mitochondrially associated based on the GO designation
mitochondrion. This fraction of mitochondrial (28 %)
versus other proteins (72 %), is consistent with published
studies using similar preparations [10, 18].
117 of these mitochondrial proteins were significantly
(p B 0.05, C2-fold change) altered between the GBM and
peritumoural-control groups: 39 proteins increased and 78
proteins decreased in GBM. All proteins are listed with
names and statistical parameters in supplementary S2,
while the numbers of proteins in each category are sum-
marised in supplementary S5. The top 40 altered proteins
(ranked by p value) are listed in Table 1 and illustrative
changes presented (Fig. 1b). Some proteins (for example,
CAT, PRDX1, GPX4) display a small variation across the
different samples, and others (for example NDUFA4,
NDUFB10, NDUFV3; all Electron Transport Chain (ETC)
complex I proteins) display a broader variation, particularly
in peritumoural-control samples.
Functional analysis of differentially expressed
mitochondrial proteins
Functional categorization of the 117 mitochondrial proteins
altered in GBM revealed two prominent functional groups
associated with antioxidants and energy metabolism.
Antioxidants
A general increase in several proteins involved in antiox-
idant defence (including CAT, PRDX1, PRDX4 and
SOD2) were observed in GBM, with the exception of
GPX4, which was significantly decreased in GBM.
Energy metabolism (ETC, TCA cycle, lipid and amino acid
metabolism)
Reductions in the levels of numerous proteins involved in
energy metabolism were observed in GBM. Multiple
components of the ETC were decreased in GBM (*40
proteins; including NDUFA4, NDUFB10, NDUFC2 and
COX6B1). Of these ETC proteins, 23 proteins were com-
ponents of ETC Complex-I. In contrast a number of pro-
teins involved in lipid metabolism (for example, ACADM,
DECR1 and SCP2) and amino acid synthesis and metab-
olism (AASS, LAP3, MTHFD1L and SHMT2) were
increased in GBM. Also several proteins integral to energy
production prior to the ETC were dysregulated in GBM:
AK2, GATM, ME2 and SUCLG2 were increased; and
CKMT1B, GLS, HK1, ME3 and SUCLA2 were decreased.
Other proteins of interest
Several proteins, for example BSG (increased in GBM),
SNCB (decreased in GBM) and IDH3 (with IDH3A,
IDH3G and IDH3B all decreased in GBM), did not fall into
an obvious functional grouping but are pertinent to tumour
pathophysiology (see ‘‘Discussion’’ section).
Interactomes of mitochondrial proteins altered in GBM
To further interrogate the proteomic data, putative inter-
actions (‘‘interactomes’’) between mitochondrial proteins
significantly altered in GBM were identified using IPA
(supplementary S6) [26]. The seven high-scoring networks
(score [20) are depicted in Fig. 2 and supplementary S7.
Three of the highest scoring interactomes were related to
components of the ETC, notably complex-I, IV and V and
a further interactome described protein–protein interactions
between the ETC and Synuclein (inter alia). The
J Neurooncol (2014) 118:247–256 249
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interactome dominated by Complex-IV proteins also
highlighted a cluster of isocitrate-dehydrogenase proteins
(IDH3A, IDH3G and IDH3B), decreased in GBM. A high
scoring network with the nuclear transcription factor
HNF4A as an inserted hub protein links 10 proteins
increased in GBM as well as 5 proteins reduced in GBM
(Fig. 2b). The other two interactomes included one with
proteins interacting with MYC and creatine-kinase, and
another with interactions between proteins involved in ion-
transport and related processes. The proteins involved in
protecting the cells from oxidative damage (for example,
CAT, SOD, PRDX1, GPX4) do not directly interact with
each other despite similar functional roles but these appear
in networks where their interactions with other proteins
(altered in GBM) have been described.
Morphology of mitochondria in GBM
The ultrastructure of mitochondria in GBM was quantita-
tively assessed and compared to control brain using
Electron Microscopy (EM). In peritumoural-control brain,
the ultrastructure of 69 % (range 44–81 %) of mitochon-
dria analysed were normal (i.e. cristae visible with no
swelling or condensed matrix) and 16 % (6–30 %) of
mitochondria were abnormal (Fig. 3). In GBM, 11 %
(4–30 %) of mitochondria were normal and 75 %
(49–88 %) of mitochondria were abnormal (Fig. 3). 15 %
of mitochondria in peritumoural-control brain and 14 % in
GBM could not be unambiguously classified as either
normal or abnormal.
Discussion
This study provides a comprehensive proteomic and mor-
phological characterisation of mitochondria in GBM.
Numerous alterations in the levels of mitochondrial pro-
teins were detected in GBM compared to control brain.
Multiple proteins associated with oxidative damage were
up-regulated in GBM and multiple proteins involved in
A B
Fig. 1 Overview of proteomic data from mitochondrial fractions.
Hierarchical clustering of the 902 proteins (normalised protein
intensities) detected by LC–MS in mitochondrial fractions of GBM
(T) and peritumoural control brain (C). Each column (in greyscale)
represents the proteomic profile (intensities of the 902 proteins) in a
single sample. Protein intensities were extracted from Progenesis
software. The dendrogram (x-axis) provides a visual representation of
sample–sample correlations, with correlated samples grouped in
branches. Note there are two main branches to this dendrogram which
precisely correspond to the two experimental groupings GBM and
peritumoural control. The data highlight that there are global
differences in the mitochondrial enriched proteome in GBM com-
pared to peritumoural control. Illustrative changes in 3 proteins
associated with oxidative damage (catalase, peroxiredoxin 1 and
glutathione peroxidase 4) and 3 proteins associated with the Electron
Transport Chain (NDUFA4, NDUFB10 and NDUFV3) in GBM
relative to peritumoural controls. Each point represents an individual
patient
250 J Neurooncol (2014) 118:247–256
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Table 1 Mitochondrial proteins altered in GBM
Protein ID Gene name Protein name p-valuea Fold changeb #
pepc
Scored
INCREASED in GBM
IPI00465436 CAT Catalase 1.45E–07 6.1 3 97
IPI00002520 SHMT2 Serine hydroxymethyltransferase 3.48E–06 5.5 2 82
IPI00419237 LAP3 Isoform1 of aminopeptidase 0.0001 5.1 7 347
IPI00026105 SCP2 Isoform SCPx Non-specific lipid-transfer protein 0.0002 5.5 2 62
IPI00215901 AK2 Adenylate kinase 2 0.0002 5.3 4 223
IPI00017726 HSD17B10 Isoform 1 3-hydroxyacyl-CoA dehydrogenase 2 0.0003 3.4 7 538
IPI00032103 GATM Glycine amidinotransferase 0.0006 6.0 9 595
IPI00096066 SUCLG2 Succinyl-CoA ligase [GDP-forming] subunit b 0.0008 10 4 167
IPI00033217 AASS Alpha-aminoadipic semialdehyde synthase 0.0012 4.5 4 184
IPI00019906 BSG Isoform 2 of Basigin 0.0014 2.1 3 137
IPI00026958 FDXR NADPH:adrenodoxin oxidoreductase 0.0015 3.2 3 107
IPI00306748 ABCB7 ATP-binding cassette sub-family B member 0.0016 2.2 2 133
IPI00011201 ME2 NAD-dependent malic enzyme 0.0023 2.2 4 309
IPI00218342 MTHFD1 C-1-tetrahydrofolate synthase 0.0024 8.3 2 102
IPI00291262 CLU Isoform1 of Clusterin 0.0027 5.7 8 545
IPI00022314 SOD2 Superoxide dismutase [Mn] 0.0029 4.5 16 1,408
IPI00910602 NEFH Isoform1 of Neurofilament heavy polypeptide 0.0032 3.5 9 377
IPI00000874 PRDX1 Peroxiredoxin-1 0.0034 2.1 13 664
IPI00003482 DECR1 2,4-Dienoyl-CoA reductas 0.0045 2.4 9 497
IPI00001960 CLIC4 Chloride intracellular channel protein 4 0.0048 6.3 10 500
IPI00005040 ACADM Medium-chain specific acyl-CoA dehydrogenase 0.0049 4.5 6 219
IPI00011937 PRDX4 Peroxiredoxin-4 0.0052 2.9 5 279
DECREASED in GBM
IPI00032904 SNCB Beta-synuclein 8.81E–05 0.2 4 355
IPI00333763 GLRX5 Glutaredoxin-related protein 5 0.0005 0.3 2 64
IPI00018246 HK1 Hexokinase-1 0.0014 0.4 48 3,168
IPI00304814 GPX4 Phospholipid hydroperoxide glutathione peroxidase 0.0016 0.4 3 84
IPI00026516 OXCT1 Succinyl-CoA:3-ketoacid-coA transferase 1 0.0018 0.4 21 1,684
IPI00658109 CKMT1B Creatine kinase, ubiquitous 0.0019 0.3 23 1,698
IPI00017802 AUH Methylglutaconyl-CoA hydratase 0.0021 0.1 2 50
IPI00217232 SUCLA2 Isoform2 succinyl-CoA ligase [ADP-forming] b 0.0025 0.3 9 357
IPI00010415 ACOT7 Isoform1 cytosolic acyl co-A thioester hydrolase 0.0026 0.4 3 113
IPI00003970 ME3 NADP-dependent malic enzyme 0.0030 0.3 9 466
IPI00011770 NDUFA4 NADH dehydrogenase [ubiquinone]1a, subunit 4 0.0035 0.4 3 78
IPI00289159 GLS Isoform KGA of Glutaminase kidney isoform 0.0038 0.3 22 1,484
IPI00216085 COX6B1 Cytochrome c oxidase subunit 6B1 0.0039 0.3 7 434
IPI00386271 SLC25A12 Calcium-binding mitochondrial carrier Aralar1 0.0039 0.3 22 1,460
IPI00020510 CISD1 CDGSH iron sulfur domain-containing protein 1 0.0041 0.3 6 272
IPI00479905 NDUFB10 NADH dehydrogenase [ubiquinone]1b, 10 0.0042 0.4 6 303
IPI00029558 NDUFC2 NADH dehydrogenase [ubiquinone] 1, C2 0.0048 0.3 2 45
IPI00003856 ATP6V1E1 V-type proton ATPase subunit E 1 0.0049 0.4 5 278
The 40 most significantly different mitochondrial proteins in GBM relative to peritumoural controls (p B 0.05, C2-fold change, ranked by p-value). For a
list of all 117 significantly altered mitochondrial proteins (p B 0.05, C2-fold change) see supplementary information S2. S2 also lists non-mitochondrial
proteins significantly altered and all unaltered proteins identified with C2 peptides
The protein accession number (IPI), gene name, and protein name are listed for each altered protein, together with: a p-value evaluated by one-way
ANOVA on intensity data (computed using Progenesis)
b Ratio of the average protein intensity in GBM and control samples, measured by Progenesis
c Number of peptides used for quantitation
d Protein identification score (calculated by Mascot)
J Neurooncol (2014) 118:247–256 251
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Localisation of proteins altered in GBM within the mitochondria
HNF4A InteractomeB
A
Score = 27
Fig. 2 Interactome analysis of mitochondrial proteins altered in
GBM. Putative localization of many of the proteins altered in GBM
within the mitochondria (based upon the mitochondrial canonical
pathway in Ingenuity Pathway Analysis (IPA); www.ingenuity.com).
Note particularly the large number of proteins that are significantly
less abundant in green (p \ 0.05 and a ratio GBM/control \0.5) in
GBM which are localised to the Electron Transport Chain Complex 1
(23 proteins). Proteins highlighted in red are significantly more
abundant in GBM. Protein–protein interactions between mitochon-
drial proteins altered in GBM. Each node (shape) represents a protein
and its association with other proteins is represented by a line. Nodes
have different shapes that represent different molecule types, for
example transcription factors, enzymes, kinases and phosphatases
(refer to Ingenuity Systems Software for detailed node information).
A high scoring interactome generated by IPA with the nuclear tran-
scription factor HNF4A as an inserted hub protein (no colour).
HNF4A linking 10 of the proteins increased (red) in GBM and 5 of
the proteins decreased (green) in GBM. For details of all of the
protein–protein interactomes generated by IPA from the 117 mito-
chondrial proteins altered, see supplementary information S6 (protein
lists) and S7 (diagrammatic representations of networks)
252 J Neurooncol (2014) 118:247–256
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energy metabolism were down-regulated. In addition a
much greater prevalence of cristolysis was observed in
GBM compared to control brain mitochondria by quanti-
tative assessment of EM images. The abnormal mito-
chondrial ultrastructure could underlie the shift in energy
generating pathways in GBM for cell survival and
progression.
The role of reactive oxygen species (ROS) and antiox-
idants in cancer is highly complex. ROS can cause DNA
damage that generates pro-oncogenic mutations, but a build
up of ROS and damaged proteins in the mitochondria can
also trigger apoptosis and autophagy [19]. ROS are a by-
product of aerobic ATP generation. Increases in GBM in
CAT, PRDX1, PRDX4 and SOD2 and a decrease in GPX4
may be a response to the increased ROS present due to the
high energy demands of the GBM. Peroxiredoxin antioxi-
dants are increased in various solid tumours [20–22] and
PRDX1 is up-regulated in GBMs compared to low-grade
gliomas. Peroxiredoxins 1 and 4 form a heterodimer and
play a key role in regulating nuclear factor kB (NFkB)
activity. NFkB is a transcription factor that modulates
oncogenesis, tumour progression and chemotherapy resis-
tance in a range of cancers [23, 24]. CAT is an enzyme that
converts H2O2 to H2O and O2 and plays a multifaceted role
in pro- and anti-apoptotic pathways. Over-expression of
CAT decreases ROS levels thereby reducing apoptosis, but
also decreases sensitivity to tumour necrosis factor alpha
(TNFa) (by reducing H2O2 [25]) which leads to increased
resistance to apoptosis. SOD2 plays a dual role in tumo-
urigenic progression, but generally overexpression of
SOD2 enhances the metastatic phenotype that is reversed
by efficient H2O2 scavenging [26]. The reduction of GPX4
is pro-oncogenic since GPX4 has been shown to halt
tumour proliferation and progression [27]. Antioxidants in
healthy cells protect against tumour genesis by preventing
oxidative damage but in cells that are already aberrant
inhibition of these antioxidants could generate catastrophic
damage by inducing apoptosis [28].
Energy pathways (comprising TCA cycle, ETC, lipid
and amino acid metabolism) were also found severely
altered in this study, in agreement with aberrant energy
metabolism in gliomas and other cancers [8, 29–32].
Fig. 3 Morphology of mitochondria in GBM. The morphology of
*150 mitochondria was assessed in each of 6 GBM and 7
peritumoural control samples using Electron Microscopy (EM).
a Percentage of normal mitochondria (i.e. where cristae are visible
throughout the mitochondria, or in at least 50 % of the mitochondrial
interior area) in peritumoural control and GBM samples (each bar
represents one sample; *** p-value = 0.0001); b Percentage of
abnormal mitochondria (i.e. with very few cristae, interior matrix
condensed and dark or round swollen with interior missing) in
peritumoural control and GBM samples (please see supplementary
information S3 for more details; *** p-value = 0.0001). c, d Repre-
sentative EM images of normal and abnormal mitochondria respec-
tively. The scale bars represent 0.5 lm
J Neurooncol (2014) 118:247–256 253
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Multiple protein alterations integral to energy production
prior to the ETC were detected (for example, AK2,
CKMT1B, GATM, GLS, HK1, ME2, ME3, SUCLA2 and
SUCLG2), with these changes emphasising a disruption
rather than a coordinated response. An increase in ME2
was found which converts malic acid and NAD ? into
pyruvate and NADH, increasing levels of NADH for the
ETC [33]. SUCLG2 which catalyses GTP, succinate and
CoA into GDP, phosphate and succinyl-CoA was markedly
increased. In contrast, a decrease was seen in the ATP
isoform SUCLA2 which reduces availability of succinyl-
CoA [34]. The increase in GATM, which catalyses pro-
duction of creatine precursor, suggests an increase in cre-
atine which can act as a phosphate store in the brain to
rapidly replenish ATP supplies [35]. Another altered pro-
tein, AK2, is found in the intermembrane space of mito-
chondria and catalyses the reversible reaction ATP and
AMP into 2ADP. When AK2 is translocated from the
nucleus to the cytoplasm it triggers apoptosis and AK2
knock-down decreases apoptosis. An increase in AK2 in
the mitochondria may favour a decrease in translocation
and therefore a decrease in apoptosis promoting tumour
growth [36].
The ETC consists of five (I–V) transmembrane protein
complexes that act in consort to transfer electrons and drive
protons into the intermembrane space to create a proton
motive gradient across the inner mitochondrial membrane
and generate ATP [37]. Numerous ETC proteins not pre-
viously identified in whole cell lysate studies were detected
in our study and the majority of these were down-regulated
in GBM (including 23 Complex-I proteins) indicating that
Complex-I function and oxidative phosphorylation (normal
aerobic respiration) is reduced in GBM.
Proteins involved in lipid metabolism (for example,
ACADM, ACOT7, DECR1, SCP2) and amino acid
metabolism (for example, AASS, LAP3, MTHFD1,
SHMT2) were up-regulated. ACADM and DECR1 are
enzymes required for the mitochondrial b oxidation of
lipids [38, 39] and SCP2 is a lipid transfer molecule that
ensures a sufficient supply of lipids to the mitochondria
[40]. AASS catalyses the metabolism of lysine to glutamate
which can be converted to a-ketoglutarate, a component of
the TCA cycle [41]. SHMT2 is a protein responsive to the
pro-oncogenic gene cMyc and catalyses the conversion of
serine to glycine with a single carbon by-product for cell
proliferation [42].
Network analysis highlighted a cluster of altered mito-
chondrial proteins associated with the nuclear transcription
factor HNF4A. Although frequently described as a tumour-
suppressor gene, HNF4A plays a role in cancer initiation
and intracellular protection against cancer-related ROS
production [9]. HNF4A has also recently been shown to be
expressed and regulated in meningioma brain tumours [43].
HNF4A interacts with proteins that are little characterised
such as ACSS3, BDH1 and FDXR, and highlights the need
for further functional investigations of these proteins in
tumour pathogenesis.
A number of mitochondrial proteins with relevance to
tumour pathophysiology were altered, including BSG,
SNCB and three Isocitrate dehydrogenase 3 forms (IDH3A,
IDH3B, and IDH3G). BSG is associated with tumour
invasiveness, metastasis, drug resistance and glycolysis
[44] and activates multiple pathways including NFkB and
JNK which stimulate matrix metalo-proteinases (MMP)
[45]. MMPs promote invasion by breaking down the
intracellular matrix. BSG levels in GBM tissue were more
than twice that of control indicating a contributory role in
tumour progression providing a potential therapeutic target.
Calveolin1 is an effective inhibitor of BSG by reducing
BSG glycosylation [46]. SNCB, known for its role in
Alzheimer’s disease, was decreased in GBM tissue 4-fold
compared to peritumoural-control tissue and inhibits
phospholipase D2 (PLD2) [47] which is oncogenic [48].
Restoration of SNCB levels may suppress tumour pro-
gression. Downregulated isoforms of IDH3 were also
noted, and IDH1 and IDH2 mutations have recently been
reported in gliomas [49]. IDH1 (cytoplasmic) and IDH2
(mitochondrial) catalyse the reaction Isocitrate-dehydro-
genase ? NADP??2-a-ketoglutarate(aKG) ? CO2 ? -
NADPH. IDH1 mutations are present in low but not high-
grade gliomas and preferentially occur in young patients
with improved prognosis [50]. Both IDH1 and IDH2
mutations have a loss-of-function and gain-of-function
consequence. No mutations of IDH3, which normally
catalyse the same reaction as IDH1/IDH2 (but use NAD?
as substrate) have been noted in gliomas, so the conse-
quence of its downregulation can only be extrapolated from
reports on IDH1/IDH2. The reduction in IDH3 would
produce the loss-of-function phenotype without the gain.
Loss-of-function causes decreased a-KG and NADH, and
the decreased a-KG results in an increased hypoxia
inducible factor 1 alpha (HIF-1a) which promotes glioma
development [51].
We describe for the first time systematic differences in
the mitochondrial proteome in GBM relative to peritumo-
ural-control tissue. Although casual perusal of the data (for
example Fig. 1b) offers tantillising suggestions of hetero-
geneity of particular protein levels in peritumoural control
or GBM, the variance within the two groups are similar to
that observed in our other studies (mouse, cell culture). The
small sample size (groups of 6) relative to the number of
proteins assessed (256) precludes meaningful subgroup
analysis, of for example IDH1 mutations, methylation
status and age related changes, despite its considerable
clinical importance. The clear demonstration of biologi-
cally coherent changes in mitochondrial proteins in GBM
254 J Neurooncol (2014) 118:247–256
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highlights the importance of further proteomic analysis of
this brain pathology.
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